Neoadjuvant chemotherapy has become the mainstream recommended treatment for advanced gastric cancer. However, due to the heterogeneity of gastric cancer, part of some patients fail to benefit from the treatment. This project aims to compare the clinical efficacy of individualized neoadjuvant therapy based on patient-derived organoid drug sensitivity assay and traditional regimen, exploring the advantages and disadvantages of these two treatments. And access the safety and clinical value of the personalized neoadjuvant therapy based on patient-derived organoid drug sensitivity assay in advanced gastric cancer.
Study Type
OBSERVATIONAL
Enrollment
54
Patients with stage III gastric cancer who need neoadjuvant chemotherapy before radical surgery are recruited. And they are treated with individualized neoadjuvant therapy under the guidance of a patient-derived organoid (PDO)-based drug sensitivity assay.
Patients with stage III gastric cancer who need neoadjuvant chemotherapy before radical surgery are recruited. In this group, patients are treated with the SOX regimen.
Shanghai Ruijin Hospttal
Shanghai, Sahnghai, China
Objective Response Rate
proportion of patients whose tumor volume reduced to a predetermined value and maintain the minimum time limit.
Time frame: an average of 1 year
postoperative complication
postoperative complication
Time frame: an average of 1 year
postoperative tumor regression grading
grade the pathological response of tumor after neoadjuvant treatment, which is usually classified according to the proportion of fibrosis and residual tumor in tumor tissues.
Time frame: an average of 1 year
3-year recurrence rate
proportion of patients who relapse within 3 years after operation
Time frame: an average of 3 year
chemotherapy tolerance and adverse reaction rate
Time frame: an average of 1 year
R0 resection rate
Time frame: an average of 1 year
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.